1. anywhere
Providing rapid, robust and reliable diagnosis
and disease monitoring and analysis at the
point of care:
By the patient, for the patient.

2. The team
• Dr
Nick
Brooks
• Dr
Ali
Salehi-­‐Reyhani
• Dr
Duncan
Casey
• David
Edwards
Project
Management
Scien0fic
/
Applica0on
Development
Itera0ve
Product
Development
Commercial
Development
IP,
Legal
&
nego0a0on
advice
Dr
Nick
Brooks
Dr
Ali
Salehi-­‐Reyhani
Dr
Duncan
Casey
Imperial
Innova>ons
David
Edwards

3. OneStart
funded
development
• The
OneStart
funding
will
be
used
to
develop
a
fully
func>onal
modular
β-­‐prototype
based
on
exis>ng
concept
designs
over
a
9
month
period.
• The
£100,000
will
allow
us
to
employ
an
engineering
based
researcher
for
9
months,
will
fund
specialist
manufacturing
consultancy
costs
and
allow
us
to
have
3
design
itera>ons
manufactured
by
external
workshops.
• This
prototype
will
form
a
plaNorm
for
applica>on
specific
op>misa>on
in
later
stages
of
the
project
and
will
facilitate
follow-­‐on
funding
applica>ons.

7. High precision, wireless, automated home based foetal monitoring
for pregnant mothers to monitor their babies themselves,
anytime and anywhere.
www.foetoh.com

8. Team
Dr. Michelle Fernandes
• Co-founder and Leader Clinical Core (MBBS, DPhil. University of Oxford)
• Expertise: Foetal neurodevelopment, foetal medicine, and antenatal monitoring
• 1+ years of experience in clinical medicine, 6+ years of experience in research medicine
• Current affiliation: FoetoH, the Nuffield Dept. of Obstetrics & Gynaecology, JR Hospital, Oxford
Dr. Ricardo Pachon
• Co-founder and Leader Technology Core (MSc, DPhil. University of Oxford)
• Expertise: pattern recognition automation, numerical mathematics
• Co-author of Chebfun, a scientific computing software.
• Current affiliation: FoetoH, CS Group AG
Medical Advisory Committee Dr. J. Hemelaar, the John Radcliffe Hospital, Oxford
Dr. G. Menezes, Snehalaya Hospital, Solur, India
Prototype Advisory Committee Ning Zhang, , University of Oxford, UK
Abhishek Appaji, BMSCE, Bangalore, India
Luis Aranzeta, CTIN, Mexico
Jomichael Porter, Stanford University, USA
Riverlite Ltd., UK
Business Advisory Committee Allan Rodriguez, Dell Inc., USA
Will Chadwick, TATA Interactive Systems, UK
Simon Bennett, Simon Bennett Associates, UK
Marks & Clerk LLP, UK

9. 2013 2014 2015 2016 2017 2018
Key
Milestone
Prototype
Product
Dev.
Pilot sales
UK
UK
launch*
European
launch*
US launch*
No. Units 1 20 90 200
Revenue 250 5,000 22,500 50,000
Expenses 100 270 880 3,700 10,000 16,000
Profit (100) (270) (630) 1,300 12,500 34,000
Cashflow (100) (370) (1,000) 300 12,800 46,800
The Case to Onestart
£100,000
Completely facilitate Phase II:
1. The development of the beta prototype
2. Preliminary laboratory & clinical testing of the beta
3. CE marking
4. The full time involvement of the team in a dedicated FoetoH office
5. Initial conversations with MNOs &larger medical device manufacturers
6. Accelerate pilot sales to Q3 2014
Figures in ‘000s, Currency GBP, *Associated with commercialization partners. Assumes retailing at £250 per unit; cost per unit of £35.

10.
HackeR
Biologics,
Cambridge,
UK
HackeR.biologics@gmail.com
Hackett Biologics has developed a proprietary
technology that stabilises stem cells at room
temperature, removing the consequences
associated with freezing

11. The
Team
• Previously
assistant
professor
of
regenera>ve
medicine
at
Linkӧping
University
in
Sweden,
scien>st/strategy
lead
at
Pfizer
Neusen>s,
Director
of
Business
Development
for
Bodymetrics.
• President
and
CSO
of
HackeR
Biologics
since
2009
and
currently
the
strategic
&
commercial
partnerships
execu>ve
at
the
Royal
Society
of
Chemistry
• PhD
and
postdoctoral
research
in
regenera>ve
medicine
and
>ssue
engineering
Dr.
Joanne
M.
HackeR,
Founder
and
CSO
• Experienced
stem
cell
biologist
at
the
University
of
Cambridge,
Linkӧping
University
and
University
of
ORawa
• Herchel
Smith
Research
Associate
–
University
of
Cambridge
• Consultant
at
HackeR
Biologics
since
2009
• PhD
and
postdoctoral
research
in
neural
stem
cell
differen>a>on
and
prolifera>on
Dr.
Ryan
B.
MacDonald,
Project
Manager
and
Scien>fic
Advisor

12. The
£100,000
investment…
Will
be
used
to:
– protect
intellectual
property
– engage
advisors,
commercial
consultants
and
collaborators
– undertake
further
stability
and
characteriza>on
studies
– perform
feasibility
studies
on
addi>onal
cell
lines
• generate
revenue
which
can
be
reinvested
to
secure
licensing
deals
with
major
companies
– provide
seed
funding
for
future
grant
applica>ons
(e.g.
TSB)

14. Natalie
Cureton
1st
year
PhD
student
in
Nanotechnology
sponsored
by
the
BBSRC
DTP
BSc
Pharmaceu>cal
Science
(2012)
Anna
King
2nd
year
PhD
student
in
Nanotechnology
sponsored
by
the
NowNano
DTC
MPhys
Physics
(2011)
Innova>on
and
Commercialisa>on
of
research
(2012)
Dr.
Lynda
Harris
BBSRC
David
Phillips
Research
Fellow
(2010-­‐2015)
PhD
(2003)
BSc
Pathobiology
(1999)

15. The
£100,000
prize
will:
§
Give
us
the
financial
support
required
to
complete
full
toxicology
and
safety
studies
§
Enable
us
to
purchase
instruments
to
assist
in
the
manufacture
of
larger
quan00es
of
LipoPep
§
Allow
us
to
explore
delivery
of
different
therapeu0cs
§
Provide
us
with
the
founda0on
required
to
take
LipoPep
through
Phase
I
and
Phase
II
clinical
trails

16. MPDx
TECHNOLOGIES
THE
MISSING
PIECE
–
Enabling
True
Point
of
Care
Diagnos4cs

17. MPDx
INTERDISCIPLINARY
TEAM
Maa
Wilkinson
MBA
Business
Development
Experienced
technical
sales
and
marke>ng
industry
professional
Devaki
Bhaaa
PhD
Scien0fic
Director
10+
yrs
diagnos>cs
start-­‐up
experience
Mul>-­‐disciplinary
exper>se
(business
&
technical)
Andy
Dixon
MSc
Chief
Engineer
Lab
automa>on
specialist
&
inventor
on
core
patents
Liz
Nyeko
MBA
Finance
Officer
Background
in
investment
banking
focused
on
healthcare
Prof
Judith
Hall
MD
OBE
Clinical
Lead,
Cardiff
Hospital
Cri>cal
care
consultant
with
30+
yrs
exper>se
in
diagnosis
and
early
interven>on
in
sepsis;
Able
to
influence
NHS
technology
adop>on
strategy
Mark
Phillips
SVP
GSK
Diagnos0cs
Senior
execu>ve
with
25+
yrs
diagnos>cs
&
pharma
experience
Early-­‐stage
biotech
business
mentor
Prof
Chris
Lowe
OBE
Director
of
Biotechnology,
University
of
Cambridge
35+
yrs
experience
in
healthcare
technology
commercialisa>on
‘Most
entrepreneurial
scien>st
of
the
UK’
Core
Team
Advisory
Board

18. USE
OF
ONESTART
£100K
• Genera0on
of
comprehensive
data
pack
comprising
key
applica0on-­‐
specific
test
results
• Significant
advances
in
next-­‐genera0on
prototype
development
• Recruitment
of
key
hires
(scien0st,
engineer)
to
enable
above
Importantly,
OneStart
financing
will
enable
MPDx
to
leverage
significant
government
grants,
crea>ng
added
value
and
posi>oning
the
company
as
an
aRrac>ve
investment
opportunity.

19. Picoto offers a comprehensive, portable newborn
monitoring solution to bring a new global standard
of care through unique sensors and intelligent data
fusion algorithms.

20. Picoto is the brainchild of several University of Oxford researchers who
specialize in data analytics, biotechnology innovation, and clinical
medicine:
The
Operational
team
The
Technology
team
The
Medical
team
We are also supported by a stellar group of advisors from
international organizations vested in the development of
better clinical care and practice
Oliver Bent
Mohammed Shahid
Jon Daly
Dr. Violeta Monasterio
Dr. Alexander Finlayson
Jayson Marwaha
Sana Fathima
Elnaz Gederi
Maxim Osipov

21. Starting with OneStart.
The One Start Prize money will be used to finish
the final prototype and validation studies.
The 100k
OneStart
Prize
Final
Prototype
Regulatory
Approval
Validation
Studies
Towards
1st Round
Seed
Funding

22. Next
genera+on
purifica+on
for
today’s
and
tomorrow’s
biotherapeu+cs
–
reducing
manufacturing
costs
by
25%

23. Oliver Hardick, EngD Founder & CEO
Current:
Postdoctoral
Fellow
at
UCL
in
Biochemical
Engineering,
a
recognised
world
expert
in
nanofibre
purifica>on
and
original
inventor
of
FibroSelect
Experience:
Director
property
company
(4
years);
Research
Engineer
–
STFC
(4
years);
Consultant
(intern)
Academics:
EngD
(UCL);
BEng
1:1
(UCL);
-­‐
Sir
Derek
Roberts
Scholarship
(2005),
Jacobs
Engineering
Award
(2008),
Finalist
Material
Science
Sapphire
Prize
(2011),
BioProducts
Laboratory
Prize
(2012)
Iwan Roberts, MEng, MRes Co-Founder & COO
Current:
Final
year
doctoral
student
in
Biochemical
Engineering
(EngD)
Experience:
IMS
Consul>ng
Group
(internship);
UK
Parliament
(adviser),
experience
in
running
technological
feasibility
studies
for
companies,
worked
with
Oliver
on
various
projects
over
the
last
7
years
Academics:
MRes
Dis>nc>on
(UCL),
MEng
1:1
(Deans
list,
UCL),
completed
entrepreneurial
MBA
modules
at
London
Business
School
Tom Haywood, CFA Co-founder & CFO
Current:
Part-­‐>me
policy
adviser
for
the
CFA
Society
of
the
UK
Experience:
Investment
Banking
(Deutsche
Bank
3
yrs);
Accoun>ng
(DeloiRe
1
yr)
Academics:
CFA
Charterholder;
MSc
in
Biodiversity
Conserva>on
and
Management
(Oxford
University);
First
class
BA
Hons
Classics
(UCL)
23
Spinout from the department of Biochemical Engineering
Team have been close friends for eight years

24. What
will
OneStart
mean
to
us?
24
We plan to develop, test at scale and then license our technology
£100k – matched with TSB SMART, will allow us to….
• Design and build an industrial scale prototype
• Test prototype at UCL using industrial facilities
• Base a demo/development rig at the Stevenage BioScience Catalyst
• Cover costs for first feasibility study with end user
OneStart advice and support will help us to execute our plan
• Network memberships will provide end user and licensee access
• Lab space can be used for prototype refinement and demonstrations
• Legal advice vital for licence model
OneStart would take Puridify to an investment inflection point
• Product proved in-house at relevant industrial scale
• Data will add value for future licensee negotiations

25. Pym
An integrated platform for mobile diagnostics,
bringing a laboratory to the phone in your hand

26. Pym
James Flewellen Irwin Zaid
ostdoctoral Researcher at
niversity of Oxford
Junior Research Fellow at Christ Church,
University of Oxford

27. Pym
and
OneStart
£100k to:
• Develop a prototype device
• Optimise urinalysis software
• Rent cloud servers for processing and storage
• Design a mobile app

28. Superior
Low
Toxic
Nano-­‐delivery
Technology
for
Stem
Cell
Therapy
STEM
Team
Name:
TECREA-­‐STEM

29. Dr. Nidhin Raj
Sales and
Marketing
Manager
Dr. Kantaraja
Chindera,
Business
Development
Director
Dr. Mittal Shah,
Stem Cell Research
Study Director
Mrs Klaudia
Muniak,
Laboratory
Manager
Miss Fadhilah
Kamaruzzaman,
R&D Scientist I
Dr. Bhagyalakshmi
Chengat Prakashbabu,
R&D Scientist II
Tecrea-Stem Team

30. How
the
100
K
will
help
you
advance
your
idea
We
already
have
in-­‐house
and
external
lab
based
evidence
demonstra0ng
that
our
technology
works
for
biomolecules
delivery
into
eukaryo0c
and
prokaryo0c
cells.
We
envision
that
with
further
op0misa0on
in
the
formula0ons,
our
technology
has
an
immense
poten0al
to
overcome
the
important
problem
of
biomolecule
delivery
in
the
stem
cell
sector,
which
will
enable
improved
research
and
transla0on
into
the
clinic.
• OneStart
funding
will
help
us
to
op0mise
condi0ons
for
improved
delivery
of
DNA,
RNA
and
protein
into
hard
to
transfect
primary
and
stem
cells.
This
would
help
to
improve
stem
cell
reprogramming
efficiency
and
advance
stem
cell
research
and
therapy.
• The
outcome
will
be
superior,
non-­‐toxic
delivery
technology
specifically
formulated
for
primary
and
stem
cell
applica0ons.
This
will
strategically
posi0on
Tecrea-­‐stem
within
the
stem
cell
sector
and
allow
us
to
capture
a
substan0al
por0on
of
a
rapidly
growing,
high
margin
market.
• Revenue
generated
from
product
sale
would
help
us
to
fund
other
applica0ons
of
our
technology,
including
in-­‐house
therapeu0c
stem
cell
reprogramming
R&D.
• Success
with
Tecrea-­‐stem
will
enable
us
to
raise
further
funding
for
other
applica0ons
of
this
technology
in
clinics
(eg
for
an0microbial
delivery).